RS51388B2 - Primena jedne kombinacije morfina i najmanje jednog opijat antagonista za tretman zavisnosti od opijata i za smanjenje neoralne zloupotrebe kod zavisnika od opijata - Google Patents
Primena jedne kombinacije morfina i najmanje jednog opijat antagonista za tretman zavisnosti od opijata i za smanjenje neoralne zloupotrebe kod zavisnika od opijataInfo
- Publication number
- RS51388B2 RS51388B2 RS20100341A RSP20100341A RS51388B2 RS 51388 B2 RS51388 B2 RS 51388B2 RS 20100341 A RS20100341 A RS 20100341A RS P20100341 A RSP20100341 A RS P20100341A RS 51388 B2 RS51388 B2 RS 51388B2
- Authority
- RS
- Serbia
- Prior art keywords
- morphine
- application according
- retarded
- naloxone
- opiate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Primena jedne nerazdvojive kombinacije od morfina ili njegovih fiziološki prihvatljivih soli i najmanje jednog opijat antagonista ili njegovih fiziološki prihvatljivih soli sa jednom bioraspoloživošću manjom od 5 % pri oralnom davanju, za proizvodnju jednog leka samo za oralno davanje pri supstitucionoj terapiji zavisnika od opiata ili zavisnika od heroina, pri čemu je opijat antagonist nalokson.
2. Primena prema patentnom zahtevu 1, naznačena time, što lek takođe smanjuje ili sprečava specifična sporedna dejstva oijata.
3. Primena prema jednom od prethodnih patentnih zahteva, naznačena time što se u njoj koriste kombinacije: retardirani morfin<*>i najmanje jedan retardirani opijat antagonist, retardirani morfin i najmanje jedan neretardirani opijat antagonist, neretardirani morfin i najmanje jedan retardirani opijat antagonist i neretardirani morfin i najmanje jedan neretardirani opijat antagonist.
4. Primena prema jednom od prethodno navedenih patentnih zahteva, naznačena time što je morfin adsorbovan na jednom polimeru i ugrađen u matricu ili da je morfin suspendovan u jednom polimeru – etilcelulozi.
5. Primena prema jednom od prethodno navedenih patentnih zahteva, naznačena time što se supstituciona terapija primenjuje na zavisnicima od heroina.
6. Primena prema jednom od prethodno navedenih patentnih zahteva, naznačena time što se radi o jednom preparatu koji se uzima ili aplicira jedan ili dva puta dnevno.
7. Primena prema jednom od prethodno navedenih patentnih zahteva, naznačena time što se morfin koristi u obliku morfin-hidrohlorida ili morfinsulfat-pentahidrata.
8. Primena prema jednom od patentnih zahteva 1 do 7, naznačena time što se nalokson koristi u obliku nalokson-hidrohlorida ili nalokson-hidrohlorid- dihidrata.
9. Primena prema jednom od prethodnih patentnih zahteva, naznačena time, što lek sadrži od 100 mg do 2000 mg retardiranog morfina.
10. Primena prema jednom od patentnih zahteva 1 do 9, naznačena time što lek sadrži 0,1 do 10 mg nalokson-a na 100 mg retardiranog morfina.
11. Primena prema jednom od prethodno navedenih patentnih zahteva, naznačena time, što se retardirani morfin i nereterdirani nalokson nalaze u obliku smeše granula, pri čemu je veličina čestica granula prioritetno od 0,1 do 2 mm.
12. Primena prema prethodno navedenom patentnom zahtevu, naznačena time, što je morfin u obliku morfinsulfat-pentahidrata i nalokson u obliku naloksonhidrohlorida ili nalokson-hidrohlorid-dihidrata.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06100578A EP1810678A1 (de) | 2006-01-19 | 2006-01-19 | Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution |
| EP07704010.3A EP1976524B2 (de) | 2006-01-19 | 2007-01-19 | Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen |
| PCT/EP2007/050540 WO2007082935A1 (de) | 2006-01-19 | 2007-01-19 | Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RS51388B RS51388B (sr) | 2011-02-28 |
| RS51388B2 true RS51388B2 (sr) | 2018-02-28 |
Family
ID=36675685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20100341A RS51388B2 (sr) | 2006-01-19 | 2007-01-19 | Primena jedne kombinacije morfina i najmanje jednog opijat antagonista za tretman zavisnosti od opijata i za smanjenje neoralne zloupotrebe kod zavisnika od opijata |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20100221339A1 (sr) |
| EP (2) | EP1810678A1 (sr) |
| CN (2) | CN103893179A (sr) |
| AT (1) | ATE465735T1 (sr) |
| AU (1) | AU2007206914B2 (sr) |
| CA (1) | CA2637458C (sr) |
| CY (1) | CY1110152T1 (sr) |
| DE (1) | DE502007003589D1 (sr) |
| DK (1) | DK1976524T4 (sr) |
| EA (1) | EA014539B1 (sr) |
| ES (1) | ES2345286T5 (sr) |
| HK (1) | HK1198744A1 (sr) |
| HR (1) | HRP20100373T4 (sr) |
| PL (1) | PL1976524T5 (sr) |
| PT (1) | PT1976524E (sr) |
| RS (1) | RS51388B2 (sr) |
| SI (1) | SI1976524T1 (sr) |
| UA (1) | UA92380C2 (sr) |
| WO (1) | WO2007082935A1 (sr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007024428A1 (de) | 2007-05-25 | 2008-11-27 | Hermann, Holger Lars, Dr. med. | Verwendung von Naloxon als Abususschutz bei Nicht-Opioiden und Nicht-Opiaten |
| CA2759870A1 (en) | 2009-04-22 | 2010-10-28 | Phoeme Gmbh | Particulate pharmaceutical composition with an opioid and an opioid antagonist |
| JP2012087101A (ja) | 2010-10-21 | 2012-05-10 | Holger Hermann Lars | オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物 |
| US9192570B2 (en) | 2013-12-20 | 2015-11-24 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| WO2015089530A1 (de) | 2013-12-20 | 2015-06-25 | G.L. PHARMA GmbH | Orale darreichungsform mit verzögerter freisetzung enthaltend morphin und naloxon |
| CN103695497B (zh) * | 2013-12-20 | 2014-09-17 | 奇方(天津)医药科技有限公司 | 纳洛酮的酶法制备及其药物组合物 |
| US20160256451A1 (en) * | 2015-03-06 | 2016-09-08 | Develco Pharma Schweiz Ag | Dosage of naloxone |
| WO2016193456A2 (en) * | 2015-06-03 | 2016-12-08 | Develco Pharma Schweiz Ag | Opioid receptor antagonist for use in treating patients with severe constipation |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1390772A (en) * | 1971-05-07 | 1975-04-16 | Endo Lab | Oral narcotic composition |
| US4769372A (en) * | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| US5580876A (en) † | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| SE9301057L (sv) | 1993-03-30 | 1994-10-01 | Pharmacia Ab | Beredning med kontrollerad frisättning |
| DE4325465B4 (de) * | 1993-07-29 | 2004-03-04 | Zenz, Michael, Prof. Dr.med. | Orales pharmazeutisches Präparat für die Schmerztherapie |
| AT403988B (de) | 1994-05-18 | 1998-07-27 | Lannacher Heilmittel | Festes orales retardpräparat |
| US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| PT914097E (pt) * | 1996-03-12 | 2002-06-28 | Alza Corp | Composicao e forma de dosagem compreendendo antagonista de opioide |
| DE59812355D1 (de) | 1997-11-06 | 2005-01-13 | Lannacher Heilmittel | Orale Retard-Präparation enthaltend Tramadol sowie Verfahren zu ihrer Herstellung |
| TR200001942T2 (tr) * | 1997-12-22 | 2000-11-21 | Euro-Celtique, S.A. | Opioid agonist/antagonist kombinasyonlar |
| CN1204890C (zh) * | 1997-12-22 | 2005-06-08 | 欧罗赛铁克股份有限公司 | 防止阿片样物质滥用的方法 |
| WO1999040898A2 (en) | 1998-02-12 | 1999-08-19 | Centrapharm Inc. | Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect |
| SI2283842T1 (sl) * | 2000-02-08 | 2015-07-31 | Euro-Celtique S.A. | Oralne formulacije opioidnih agonistov, varne pred zlorabo |
| EP1387673B1 (en) † | 2001-05-11 | 2010-12-29 | Endo Pharmaceuticals Inc. | Abuse-resistant controlled-release opioid dosage form |
| US20030044458A1 (en) † | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| LT2425821T (lt) | 2002-04-05 | 2017-07-25 | Euro-Celtique S.A. | Farmacinis preparatas, turintis oksikodono ir naloksono |
| SI1551372T1 (en) | 2002-09-20 | 2018-08-31 | Alpharma Pharmaceuticals Llc | SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES |
| US20050191244A1 (en) * | 2002-10-25 | 2005-09-01 | Gruenenthal Gmbh | Abuse-resistant pharmaceutical dosage form |
| US20040110781A1 (en) * | 2002-12-05 | 2004-06-10 | Harmon Troy M. | Pharmaceutical compositions containing indistinguishable drug components |
| AT503858B1 (de) | 2003-06-05 | 2008-08-15 | Lannacher Heilmittel | Verfahren zur herstellung einer festen oralen pharmazeutischen zusammensetzung, enthaltend ein jodsalz |
| EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
| KR100905511B1 (ko) | 2005-01-28 | 2009-07-01 | 유로-셀띠끄 소시에떼 아노님 | 알코올 저항성 제형 |
| FR2889810A1 (fr) * | 2005-05-24 | 2007-02-23 | Flamel Technologies Sa | Forme medicamenteuse orale, microparticulaire, anti-mesurage |
| GB2471801B (en) | 2006-05-25 | 2011-02-16 | Alpharma | Process useful in the preparation of morphine antagonists |
| SI2484346T1 (sl) | 2006-06-19 | 2017-05-31 | Alpharma Pharmaceuticals Llc | Farmacevtski sestavki |
-
2006
- 2006-01-19 EP EP06100578A patent/EP1810678A1/de not_active Withdrawn
-
2007
- 2007-01-19 CN CN201410124301.5A patent/CN103893179A/zh active Pending
- 2007-01-19 AU AU2007206914A patent/AU2007206914B2/en not_active Ceased
- 2007-01-19 DE DE502007003589T patent/DE502007003589D1/de active Active
- 2007-01-19 US US12/161,397 patent/US20100221339A1/en not_active Abandoned
- 2007-01-19 UA UAA200810463A patent/UA92380C2/ru unknown
- 2007-01-19 EA EA200870182A patent/EA014539B1/ru unknown
- 2007-01-19 AT AT07704010T patent/ATE465735T1/de active
- 2007-01-19 CA CA2637458A patent/CA2637458C/en active Active
- 2007-01-19 PT PT07704010T patent/PT1976524E/pt unknown
- 2007-01-19 RS RS20100341A patent/RS51388B2/sr unknown
- 2007-01-19 SI SI200730285T patent/SI1976524T1/sl unknown
- 2007-01-19 CN CNA2007800026334A patent/CN101370503A/zh active Pending
- 2007-01-19 PL PL07704010T patent/PL1976524T5/pl unknown
- 2007-01-19 WO PCT/EP2007/050540 patent/WO2007082935A1/de not_active Ceased
- 2007-01-19 EP EP07704010.3A patent/EP1976524B2/de active Active
- 2007-01-19 HR HRP20100373TT patent/HRP20100373T4/hr unknown
- 2007-01-19 ES ES07704010.3T patent/ES2345286T5/es active Active
- 2007-01-19 DK DK07704010.3T patent/DK1976524T4/en active
-
2010
- 2010-06-24 CY CY20101100578T patent/CY1110152T1/el unknown
-
2014
- 2014-12-04 HK HK14112247.0A patent/HK1198744A1/xx unknown
-
2016
- 2016-06-20 US US15/187,374 patent/US10507205B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2637458A1 (en) | 2007-07-26 |
| SI1976524T1 (sl) | 2010-08-31 |
| US20100221339A1 (en) | 2010-09-02 |
| PL1976524T5 (pl) | 2017-12-29 |
| EA014539B1 (ru) | 2010-12-30 |
| EP1976524A1 (de) | 2008-10-08 |
| US20170136005A1 (en) | 2017-05-18 |
| PL1976524T3 (pl) | 2010-10-29 |
| DK1976524T4 (en) | 2016-12-05 |
| CA2637458C (en) | 2015-03-10 |
| EP1976524B1 (de) | 2010-04-28 |
| DK1976524T3 (da) | 2010-08-09 |
| HRP20100373T1 (en) | 2010-08-31 |
| PT1976524E (pt) | 2010-07-05 |
| AU2007206914B2 (en) | 2012-08-23 |
| US10507205B2 (en) | 2019-12-17 |
| CN103893179A (zh) | 2014-07-02 |
| UA92380C2 (ru) | 2010-10-25 |
| EP1976524B2 (de) | 2016-08-10 |
| WO2007082935A1 (de) | 2007-07-26 |
| DE502007003589D1 (de) | 2010-06-10 |
| RS51388B (sr) | 2011-02-28 |
| ES2345286T3 (es) | 2010-09-20 |
| EA200870182A1 (ru) | 2009-02-27 |
| AU2007206914A1 (en) | 2007-07-26 |
| HK1198744A1 (en) | 2015-06-05 |
| HRP20100373T4 (hr) | 2016-12-16 |
| CY1110152T1 (el) | 2015-01-14 |
| EP1810678A1 (de) | 2007-07-25 |
| ES2345286T5 (es) | 2017-04-25 |
| ATE465735T1 (de) | 2010-05-15 |
| CN101370503A (zh) | 2009-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2239417C2 (ru) | Опиоидные анальгетики с контролируемым высвобождением активных веществ | |
| CN105491885B (zh) | 疼痛药物组合及其用途 | |
| JP2009143964A5 (sr) | ||
| CA2689101C (en) | Modifying drug release in suspensions of ionic resin systems | |
| RU2011104146A (ru) | Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи | |
| US20020143028A1 (en) | Analgesic combination of oxycodone and nabumetone | |
| ME01262B (me) | OBLIK ZA DOZIRANJE KOJI SADRŽI OKSIKODON l NALOKSON | |
| JP2005512995A5 (sr) | ||
| WO2007013975A3 (en) | Composition containing an opioid agonist and a partial opioid agonist, preferably buprenorphine , for controlling abuse of medications | |
| IL221795B (en) | Use of a pharmaceutical preparation of methylnaltrexone or a salt thereof for the preparation of a medicine for the treatment of side effects of treatment with opiates | |
| AU2005251733A1 (en) | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs decongestants and non-sedating antihistamines | |
| HRP20100373T4 (hr) | Upotreba kombinacije morfina s najmanje jednim opijatnim antagonistom u liječenju ovisnosti o opijatima i u sprječavanju neoralne zloupotrebe opijata kod ovisnika opijatima | |
| CN101534809A (zh) | 取代的2-氨基1，2，3，4-四氢化萘在制备预防、减轻和/或治疗各类疼痛的药物中的用途 | |
| WO2007123865A3 (en) | Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists | |
| RU2011138490A (ru) | Фармацевтические композиции с мгновенным высвобождением, содержащие оксикодон и налоксон | |
| ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
| WO2007031887A3 (en) | Extended release pharmaceutical composition of metformin and a process for producing it | |
| JP2006500395A (ja) | 組み合わされた即時放出及び徐放の鎮痛組成物 | |
| WO2007145863A3 (en) | Sustained release formulation of naltrexone | |
| JP2011516544A5 (sr) | ||
| HRP20140596T1 (hr) | Uporaba opioidnih antagonista za pripravu lijeka za lijeäśenje degenerativnih bolesti mrežnice | |
| JP2009526833A5 (sr) | ||
| US9101577B2 (en) | Analgesic pharmaceutical composition for oral administration | |
| JP2018515456A5 (sr) | ||
| RU2003135201A (ru) | Применение антагониста опиоидов налтрексона для предупреждения и контроля побочных воздействий, вызванных опиоидами |